1. PainReform's R&D assessment supports the LayerBio ocular drug platform. 2. The matrix can incorporate various drugs, enhancing postoperative cataract care. 3. LayerBio's OcuRing aims to reduce reliance on medicated eye drops. 4. Improved patient compliance is vital, especially for elderly cataract patients. 5. Future developments may follow, focusing on multi-drug loading capabilities.
FAQ
Why Bullish?
The successful R&D assessment indicates strong potential for PRFX's future revenue growth. Historical precedents show that innovative drug delivery systems can significantly increase market share and investor confidence.
How important is it?
The advancements in drug delivery could revolutionize cataract postoperative treatment, positioning PRFX favorably within healthcare investment priorities.
Why Long Term?
While immediate sales may not manifest, the technology's implications could expedite product commercialization and long-term revenues, similar to past technological integrations in pharma.
PainReform's LayerBio Platform Validated for Multi-Drug Ocular Delivery
On December 10, 2025, PainReform Ltd. (Nasdaq: PRFX) announced a significant milestone from its pharmaceutical division, confirming the capacity of its LayerBio platform to accommodate various drug entities in a sustained-release matrix. This innovative drop-less ocular drug-delivery system aims to enhance therapeutic efficacy while simplifying postoperative care for cataract surgery patients by significantly reducing, or potentially eliminating, the reliance on traditional medicated eye drops.
Key Findings from R&D Assessment
The R&D assessment highlighted the successful integration of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs)—two critical therapeutic classes routinely used post-cataract surgery—into the polymer matrix platform. These results bolster the long-term potential of LayerBio's technology in delivering multiple drugs, pointing to a promising future in ocular therapeutics.
- Multi-Drug Capability: The LayerBio platform demonstrated feasibility for incorporating different drug entities.
- Enhanced Patient Comfort: Controlled drug release aims to improve patient compliance, particularly among elderly patients.
- Reduced Dosing Risks: The platform provides effective dosing at a fraction of the amount usually needed in eye drop regimens.
Implications for Cataract Surgery Patients
The pre-fabricated OcuRing, developed by LayerBio, is designed for intraocular placement during cataract surgery. This approach enables sustained and targeted drug delivery to ocular tissues, enhancing postoperative management. Consequently, the technology has the potential to significantly reduce discomfort and lower the risk associated with higher volumes of eye drops, thereby addressing a critical unmet need in patient care.
“Our assessment confirms one of the core reasons for our LayerBio investment—the underlying platform can be engineered to carry more than one drug at the same time, including different types of drugs, offering meaningful long-term versatility,” stated Ehud Geller, Chairman of PainReform. He emphasized that while the current focus remains on the OcuRing-K for addressing pain and inflammation post-surgery, the capability for multi-drug delivery strengthens the foundation for future development initiatives aimed at simplifying complex drop regimens.
About PainReform Ltd.
PainReform Ltd. (Nasdaq: PRFX) is dedicated to the reformulation of established therapeutics and the development of innovative solutions through its AI-driven DeepSolar platform. The company's pharmaceutical initiatives revolve around a proprietary extended-release drug delivery system designed to offer prolonged pain relief post-surgery while minimizing the need for frequent dosing. Additionally, the DeepSolar platform focuses on optimizing energy consumption, particularly in solar-integrated environments, reflecting PainReform's commitment to impactful technological applications across key sectors.
Forward-Looking Statements
This press release includes forward-looking statements regarding PainReform’s strategic outlook and the long-term potential of the OcuRing-K product. Such statements are subject to risks and uncertainties that may affect actual outcomes, including the company’s ability to secure additional funding, the success of its product candidates, and changes in market conditions. Investors should consider these factors carefully when evaluating investment in shares of PRFX.
Contact Information
For further inquiries, please contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com
Dr. Ehud Geller
Chairman and Interim CEO, PainReform Ltd.
Tel: +972-54-4236711
Email: egeller@medicavp.com